Dr. Ahmad Tarhini, MD

Dr. Tarhini practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Tarhini's NPI, 1811934755, was assigned on May 31, 2006. Dr. Tarhini graduated from Kaunas Medical Institute in 1999. Dr. Tarhini's Pennsylvania license number on file is MD424978.

Dr. Tarhini's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Tarhini also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Tarhini's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Tarhini to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tarhini practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tarhini's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tarhini is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Tarhini's licenses on file in 4 states: Pennsylvania, Florida, Georgia and Ohio.

Dmand AI lists chronic leukemia, lymphoma and prostate cancer among the conditions Dr. Tarhini treats.

CMS data shows 400 Medicare services from Dr. Tarhini across 3 procedure codes in 2024, all of them office visits, for 221 Medicare patients. Medicare paid $44,802 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 221 Medicare patients who saw Dr. Tarhini in 2024. The largest group is 65 to 74, with 100 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tarhini's median patient age at 73, with 32% women.

In 2024, Dr. Tarhini wrote 65 Medicare Part D claims for 43 patients. 71% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $119 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Tarhini for performance year 2024, reported as part of a group. Dr. Tarhini accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 177 papers to Dr. Tarhini, published from 2007 to 2025. 2023 was the busiest year, with 14. The most frequent topics are Melanoma, Skin Neoplasms and Immunotherapy. Dr. Tarhini has published most often in J Clin Oncol. Dr. Tarhini's most frequent co-authors are Vernon K. Sondak, MD, Hussein Abdul-Hassan Tawbi, MD and Michael B. Atkins, MD.

Dmand AI links Dr. Tarhini to 29 clinical trials, 8 of them phase 1 studies. 8 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 8.

CMS Open Payments shows 255 general payments to Dr. Tarhini from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Merck Sharp & Dohme Corporation paid the most, $72,808. It also lists 23 research payments totaling $79,992 from 2017 to 2025.

Dr. Tarhini graduated from Kaunas Medical Institute in 1999. Dr. Tarhini is a member of ASCO.

Dr. Tarhini is in network with 12 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.